Therefore, following the rationale in our previous NMA addressing the risk of neurodegenerative diseases related to GLP-1 receptor agonists and SGLT2 inhibitor use [13], this NMA aims to provide evidence about the comparative risk of hearing loss by GLP-1 receptor agonists and SGLT2 inhibitor use. This evidence concerns the gene SLC5A2 and neurodegenerative disease.